Russell Pachynski is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Medical Oncology, Ste 7a, 7b, 7c
Saint Louis, MO 631101032
Telephone
800-647-2098Registry record last updated 17 Apr 2025.
Clinical trials
- Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Sponsor: Washington University School of Medicine
- Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Sponsor: Washington University School of Medicine
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dendreon Pharmaceuticals LLCProgram year20255 payments
- Exelixis Inc.Program year20252 payments
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
28.6%Corticosteroid28.6%Dexamethasone sodium phosphate91%Dexamethasone9%Part D + Part B<11 patientsMetabolism & gastrointestinal
27.9%Corticosteroid19.8%Prednisone100%Part D≥37 patientsProton pump inhibitor4.8%Pantoprazole Sodium100%Part D<11 patients+ 1 more class in this area
Nervous system
23.3%Opioid Agonist10.7%Tramadol Hcl40%Oxycodone Hcl38%Morphine Sulfate Er22%Part D<11 patientsPhenothiazine4.9%Prochlorperazine Maleate100%Part D≥16 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer
Washington University
FY2026$602,200R01CA286127 - Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer
Washington University
FY2025$610,019R01CA286127
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”